Topics to be discussed include:
- Lessons to be learned from recent CIA agreements: Separating out individual considerations and identifying across-the-board negotiation points
- How much of your global and domestic business will be covered by the CIA?
- What kind of monitoring controls and systems need to be implemented?
- What kind of restraints on HCP relationships can you enter into?
- What trends about OIG priorities can be extrapolated from recent CIAs?
- Determining the ramifications of multi-violators
- Distinguishing between boiler-plate and investigation specific provisions
- What provisions are subject to modification based on company specific factors?
- Insights into what provisions have been successfully tailored by other companies
- Creating a cooperative relationship with your appointed monitors and communicating effectively with the OIG during the pendency of the CIA
- Proactively fortifying your compliance system based on the requirements of other pharmaceutical and medical device CIAs before negotiating with the government
- Living under a CIA
- Understanding the effects
- Getting the Board of Directors involved
- Discussing the likelihood of “probation” becoming a new standard
- Preparing for potential tax consequences to settlements – distinguishing between repayments and penalties
- Evaluating what constitutes a “reportable event”
- Setting up internal review organizations and data collection as to implementation of programs
- Preparing for allegations of a breach
- Identifying who can enforce CIA conditions
- Comparing jurisdictional views on whether a breach of a CIA can give rise to an action under the False Claims Act
- Updating investigators on what systems have been implemented and providing data on efficacy
- Retaining independent review organizations
For more information, visit the event website.
People
Related Insights
17 April 2025
Tariff & International Trade Resource
The Non-Compliant Cat in the Hat
So, just before Easter, in 1957, a little book you may have heard of, called The Cat in the Hat, made its first appearance. Theodore Geisel — writing under the name “Dr. Suess” — later said that of all his children’s books, he was proudest of this one, because “it had something to do with the death of the Dick and Jane primers,” which he thought would bore any child to tears.
17 April 2025
Manufacturing Industry Advisor
Foley Automotive Update and the Latest Insights on Tariffs
Foley is here to help you through all aspects of rethinking your long-term business strategies, investments, partnerships, and technology. Contact the authors, your Foley relationship partner, or our Automotive Team to discuss and learn more.
17 April 2025
Foley Viewpoints
Delaware Law on Fiduciary Duties and Stockholder Agreements
Delaware corporate law is renowned for its balance between flexibility in business arrangements and the fundamental principles of fiduciary accountability.